PF-07872444

PF-07872444 is a pneumococcal conjugate vaccine component developed by Pfizer. It consists of a specific *Streptococcus pneumoniae* capsular polysaccharide conjugated to a carrier protein, typically CRM197. The drug is being developed as part of an expanded multivalent pneumococcal conjugate vaccine (PCV) regimen, which aims to provide broader protection than the current 20-valent vaccine (Prevenar 20) by including additional serotypes. PF-07872444 is currently being evaluated in Phase 3 clinical trials in healthy infants as one of several new conjugate components in an expanded multivalent vaccine candidate designed to prevent invasive pneumococcal disease and pneumonia.